Stichting Rega Vzw

Ceskoslovenska Akademie Ved

Institute of Organic Chemistry and Biochemistry of the Academy of

Rega Stichting, V.z.w.

Mitsubishi Kasei Corporation

Richter Gedeon Vegyeszeti Gyar Rt

The University of Birmingham

The United States of America As Represented by the Department of Health

The Government of the United States of America

Stichting Rega Vzw (rega)

Rega Institut

Rega Instituut Vzw

Erik D De Clercq

Antonin Holy

Masanori Baba

Richard T Walker

Ivan Rosenberg

Hiromichi Tanaka

Tadashi Miyasaka

Masaru Ubasawa

Piet A Herdewijn

Sandor Gorog

Samuel Broder

Miklos Low

Albert S Jones

Miklos Nagy

Jan M Balzarini

Masaaki Iigo

Arthur Albert Van Aerschot

Sandorne Gyorgyi

Jindrich Jindrich

Jan Maria Balzarini

Jan Marie Balzarini

Piet Andre Herdewlin

Gabriel A Verhelst

Philip J Barr

Novel PMP, PME and HPMP and related compounds containing N-6 substituted 2,6-diaminopurine and adenine bases are provided. These compounds are useful in a variety of utilities, including as intermediates in the preparation of flame retardants, diagnostic reagents and therapeutics, including antivirals. Of particular note are compounds otherwise not known to possess anti-DNA viral activity that become potent inhibitors of DNA viruses upon substitution of the N-6 site, thereby providing a novel and unexpected and surprising use for such compounds.

N.sup.6 - substituted nucleotide analagues and their use

This invention relates to new nucleotide analogues and solves the technical problem of their use as biologically active compounds. The subject of this invention are N-(2-phosphonylmethoxyethyl) and N-(3-hydroxy-2-phosphonylmethoxypropyl) derivatives of pyrimidine and purine bases, easily accessible from heterocyolic bases and their N-(2-hydroxyethyl) or N-(2,3-dihydroxypropyl) derivatives. Some of the compounds, according to this invention, exhibit a marked antiviral activity or can be converted into such active compounds by chemical transformations.

9-(2-phosphonylmethoxyethyl) guanine

N-(3-Fluoro-2-phosphonylmethoxypropyl) derivatives of purine and pyrimidine heterocyclic bases, method of producing them and their use as active principles of drugs. The invention relates to suppression of multiplication of viruses, particularly retroviruses, by application of the new compounds, N-(3-fluoro-2-phosphonylmethoxypropyl) derivatives of purine and pyrimidine heterocyclic bases. These compounds are obtained by the reaction of the N-(3-fluoro-2-hydroxypropyl) derivatives of purine and pyrimidine heterocyclic bases with diesters of p-toluenesulfonyloxymethylphosphonic acid in the presence of sodium hydride.

N-(3-fluoro-2-phosphonylmethoxypropyl) derivatives of purine and

It has been found that 1,5-anhydrohexitol nucleoside analogues, wherein a 4-substituted-2,3,4-trideoxy-1,5-anhydrohexitol is coupled via its 2-position to the heterocyclic ring of a pyrimidine or purine base, exhibit remarkable anti-viral properties against herpes viruses, pox viruses and related viruses. The new nucleoside analogues are represented by the general formula I ##STR1## wherein B is a heterocyclic ring derived from a pyrimidine or purine base, X represents H, N.sub.3, F, Cl, Br, I, amino, --NHR.sup.2, --N(R.sup.2).sub.2, --OR.sup.2, --SR.sup.2 or CN, R.sup.1 and R.sup.2 are the same or different and hydrogen, alkyl, acyl or phosphate groups are represented, or wherein X is hydrogen and a double bond is situated between the 3- and 4- position of the 1,5-anhydrohexitol ring. Pharmaceutically acceptable salts and esters thereof are included.

Method of using 1,5-anhydrohexitol nucleoside analogues to treat viral

This invention relates to new nucleotide analogues and solves the technical problem of their use as biologically active compounds. The subject of this invention are N-(2-phosphonylmethoxyethyl) and N-(3-hydroxy-2-phosphonylmethoxypropyl) derivatives of pyrimidine and purine bases, easily accessible from heterocyclic bases and their N-(2-hydroxyethyl) or N-(2,3-dihydroxypropyl) derivatives. Some of the compounds, according to this invention, exhibit a marked antiviral activity or can be converted into such active compounds by chemical transformations.

N-phosphonylmethoxyalkyl derivatives of pyrimdine and purine bases and a

1,5-Anhydrohexitol nucleoside analogues represented by the general formula I: ##STR1## wherein the hexitol has the D-configuration and the carbon atom on which the base moiety and the X substituent stand both have the (S)-configuration and further wherein:

1,5-anhydrohexitol nucleoside analogues

The disclosure concerns pyrimidine derivatives represented by the following general formulas [I] and [I'] and having antiviral activity, particularly antiretroviral activity such as anti-HIV activity: ##STR1## and pharmaceutical compositions having antiviral activity and comprising the above-described derivative(s) as an active ingredient.

Pyrimidine derivatives and anti-viral agent containing the same as

A pyrimidine nucleoside derivative and pharmaceutically acceptable salt thereof specified by the presence of ethyl group or isopropyl group at 5-position of the pyrimidine ring and the presence of a (substituted) phenylthio or a (substituted) benzyl group at 6-position of the pyrimidine ring is provided. The pyrimidine nucleoside derivative and pharmaceutically acceptable salt thereof show a markedly higher anti-retroviral activity than conventional analogous compounds and have a relatively low toxicity against the host cells, and therefore, are useful as an active ingredient of antiviral agent.

Pyrimidine nucleoside derivative and antiviral agent containing the

Sulphated vinyl polymers such as sulphated polyvinylalcohol, sulphated copolymers of (meth)acrylic acid and vinylalcohol, and pharmaceutically acceptable salts thereof, have an antiviral effect against human immunodeficiency virus and may therefore be used as a therapeutic agent for treating retrovirus infections like AIDS and AIDS-related diseases. Their antiviral activity is apparently based on inhibition of virus adsorption; their inhibitory effect on giant cell formation is stronger than that of dextran sulphate.

Sulphated vinyl polymer in composition for treating retroviral infections

Sulphated vinyl polymers in compositions for treating retroviral

This invention relates to new nucleotide analogues and solves the technical problem of their use as biologically active compounds. The subject of this invention are N-(2-phosphonylmethoxyethyl) and N-(3-hydroxy-2-phosphonylmethoxypropyl) derivatives of pyrimidine and purine bases, easily accessible from heterocyclic bases andd their N-(2-hydroxyethyl) or N-(2,3-dihydroxypropyl) derivatives. Some of the compounds, according to this invention, exhibit a marked antiviral activity or can be converted into such active compounds by chemical transformations.

N-phosphonylmethoxyalkyl derivatives of pyrimidine and purine bases and

The antiviral activity of 5-fluoro-uracil, 5-fluoro-2'-deoxyuridine and similar thymilydate synthetase inhibitors towards herpes viruses can be potentiated dramatically by combining these compounds with compounds having viral thymidine kinase inhibiting activity.

Combinations of TS-inhibitors and viral TK-inhibitors in antiherpetic

The compound 2',3'-dideoxycytidinene has an antiviral effect against human immunodeficiency virus (HIV) and may therefore be used as a therapeutic agent for treating AIDS and related diseases.

Therapeutic application of dideoxycytidinene

6-substituted acyclopyrimidine nucleoside derivatives and antiviral

The antitumor activity of 5-fluorouracil and its precursors against adenocarcinomas can be potentiated without a corresponding increase in toxicity by combining these compounds with (E)-5-(2-bromovinyl)-uracil or a precursor thereof. The combinations may have the form of a single composition or two separate compositions.

Growing community of inventors

Louvain, Belgium

Erik D De Clercq